When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Lubiprostone - Wikipedia

   en.wikipedia.org/wiki/Lubiprostone

   A 2018 pooled analysis from three phase III, randomized, double-blind, placebo-controlled studies on usage for Opioid-Induced Constipation, found that the numbers of patients reporting adverse effects were similar in both the lubiprostone and placebo treatment groups for all opioid classes (P ≥ 0.125); however, gastrointestinal adverse ...

3. Naloxegol - Wikipedia

   en.wikipedia.org/wiki/Naloxegol

   Naloxegol (INN; PEGylated naloxol; [4] trade names Movantik and Moventig) is a peripherally acting μ-opioid receptor antagonist developed by AstraZeneca, licensed from Nektar Therapeutics, for the treatment of opioid-induced constipation. [5] It was approved in 2014 in adult patients with chronic, non-cancer pain. [6]

4. Bevenopran - Wikipedia

   en.wikipedia.org/wiki/Bevenopran

   Bevenopran (INN, USAN) (former developmental code names CB-5945, ADL-5945, MK-2402, OpRA III) is a peripherally acting μ-opioid receptor antagonist that also acts on δ-opioid receptors and was under development by Cubist Pharmaceuticals for the treatment of chronic opioid-induced constipation.

5. Oxycodone - Wikipedia

   en.wikipedia.org/wiki/Oxycodone

   In children between 11 and 16, the extended-release formulation is FDA-approved for the relief of cancer pain, trauma pain, or pain due to major surgery (for those already treated with opioids, who can tolerate at least 20 mg per day of oxycodone) – this provides an alternative to Duragesic , the only other extended-release opioid analgesic ...

6. Results from Phase III Studies of Naloxegol for Treatment of ...

   www.aol.com/2013/05/21/results-from-phase-iii...

   Results from Phase III Studies of Naloxegol for Treatment of Opioid-Induced Constipation Presented at Digestive Disease Week 2013 ORLANDO, Fla.--(BUSINESS WIRE)-- AstraZeneca (NYS: AZN) today ...

7. Functional gastrointestinal disorder - Wikipedia

   en.wikipedia.org/wiki/Functional...

   C2. Functional constipation; C3. Functional diarrhea; C4. Functional abdominal bloating/distension; C5. Unspecified functional bowel disorder; C6. Opioid-induced constipation; D. Centrally mediated disorders of gastrointestinal pain. D1. Centrally mediated abdominal pain syndrome (CAPS) D2. Narcotic bowel syndrome (NBS)/ Opioid-induced GI ...